Article

The clinical, genomic, and transcriptomic landscape of BRAF mutant cancers

2023-09-18

Abstract excerpt

<h4>Background</h4> BRAF mutations are classified into 4 molecularly distinct groups, and Class 1 (V600) mutant tumors are treated with targeted therapies. Effective treatment has not been established for Class 2/3 or BRAF Fusions. We investigated whether BRAF mutation class differed according to clinical, genomic, and transcriptomic variables in cancer patients. <h4>Methods</h4> Using the AACR GENIE (v.12) canc...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 592e838f-cc62-5433-a5c7-f87cc73150c2
DOI: 10.1101/2023.09.15.557847

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The clinical, genomic, and transcriptomic landscape of BRAF mutant cancersDOI 10.1101/2023.09.15.557847Read

Prevalence of class I-III BRAF mutations among 114,662 cancer patients in a large genomic database.Semantic proximity Read

Unraveling BRAF alterations: molecular insights to circumvent therapeutic resistance across cancer typesSemantic proximity Read

Clinical activity of MAPK targeted therapies in patients with non-V600 BRAF mutant tumorsSemantic proximity Read

BRAF Mutations: Oncogenic Drivers in Solid TumorsSemantic proximity Read

Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing.Semantic proximity Read

CDK4/6 and SHP2 mediate BRAF/MEK inhibitor resistance in Class 2 and 3 BRAF mutant cancersSemantic proximity Read

Targeting the multifaceted BRAF in cancer: New directions.Semantic proximity Read

Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.Semantic proximity Read

Spectrum of BRAF Aberrations and Its Potential Clinical Implications: Insights From Integrative Pan-Cancer AnalysisSemantic proximity Read

Clinical Activity of Mitogen-Activated Protein Kinase–Targeted Therapies in Patients With Non–V600 BRAF-Mutant TumorsSemantic proximity Read

Characterization of the BRAF interactome identifies BRAF <sup>V600E</sup> <=>TP53 interaction in melanomaSemantic proximity Read

Distinct clinical and genomic profiles of braf mutation subtypes in Chinese colorectal cancer: a retrospective cohort study with cross-population validation.Semantic proximity Read